Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MY008211A QTc study in healthy volunteers
NCT06543459Phase 1Not yet recruiting
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MY-008 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoint: Change from baseline in QTcF corrected for placebo up to 2 weeks. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
MY-008
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06543459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543459.